Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer's drug, Kisunla, has blockbuster potential, and if efforts at early ...

Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...

Developed in partnership with agency Wieden+Kennedy Portland, Lilly’s Good Days officially launched on Sunday. The spot will air in the final slot before showings of Wicked: For Good and during the ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% during the ...

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the ...